产品名称
Moxonidine, European Pharmacopoeia (EP) Reference Standard
SMILES string
Clc1nc(nc(c1N=C2NCCN2)OC)C
InChI
1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
InChI key
WPNJAUFVNXKLIM-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
moxonidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Moxonidine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scintigraphic diagnosis of Erdheim-Chester disease.
Hans Balink et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(16), e470-e472 (2011-03-23)
P Ernsberger
Journal of cardiovascular pharmacology, 35(7 Suppl 4), S27-S41 (2001-05-11)
The I1-imidazoline receptor is a novel neurotransmitter receptor found mainly in the brainstem, adrenal medulla and kidney. The actions of moxonidine are described at the level of individual biomolecules, cells, tissues, organs and finally with integrative functions. The receptor functions
M Schachter et al.
Drug safety, 19(3), 191-203 (1998-09-25)
Classical centrally acting antihypertensive agents lower blood pressure by reducing excessive sympathetic tone; however, their clinical use is limited by an adverse effect profile resulting from alpha2-adrenoceptor agonism. Moxonidine is a new centrally acting agent showing selective agonism of imidazoline
Jun-Feng Peng et al.
Cardiovascular research, 89(2), 473-481 (2010-09-11)
The depressor action of the centrally antihypertensive drug moxonidine has been attributed to activation of I(1)-imidazoline receptor in the rostral ventrolateral medulla (RVLM). The objective of this study was to determine the role of the γ-aminobutyric acid (GABA) mechanisms in
B N Prichard et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 15(1), S47-S55 (1997-01-01)
Imidazoline I1-receptor agonism represents a new mode of antihypertensive action to inhibit peripheral alpha-adrenergic tone by a central mechanism. Adrenaline, noradrenaline and renin levels are reduced, a finding consistent with central inhibition of sympathetic tone. Acute haemodynamic studies indicate that
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持